Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. The median follow-up duration was approximately 6 months. The estimated ...
4th European Breast Cancer Conference - Hamburg, Germany. March 17 2004: New data presented today 1,2, indicate that preoperative (neoadjuvant) treatment with ARIMIDEX TM (anastrozole) results in ...
Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently licensed medication for the prevention of breast cancer. Research ...
A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, ...
At the virtual San Antonio Breast Cancer Symposium, researchers presented 12-year results for tamoxifen versus anastrozole [Arimidex], which demonstrated no significant difference in terms of disease ...
SAN ANTONIO — Anastrozole reduced breast cancer risk by 49% compared with placebo for postmenopausal women at high risk for the disease, according to long-term results of the randomized controlled ...
Mediafeed on MSN
Testosterone drug comparison: Enclomiphene vs Anastrozole
This article was reviewed by Mike Bohl, MD, MBA, MPH, MS, ALM. Enclomiphene vs Anastrozole: Drug Comparison Compare common ...
Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, ...
NEW YORK (Reuters Health) - After approximately 8 years, postmenopausal women with hormone-sensitive breast cancer who received (Arimidex), generically known as anastrazole, had a lower risk of ...
Nearly 300,000 women in England will be offered a preventative pill to help them avoid breast cancer. The drug, anastrozole, has been available for years as a breast cancer treatment, and had already ...
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial concluded that anastrozole was more effective than tamoxifen in preventing recurrence of breast cancer. The ATAC Trialists' Group recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback